InsiderTrades

Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2024-10-22 00:00:00 ET · period of report 2024-10-18 · accession 0001415889-24-025501 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-10-22 2024-10-18 ELVN Hohl Benjamin CFO M - OptEx $2.48 +814 814 New +$2,019
D 2024-10-22 2024-10-18 ELVN Hohl Benjamin CFO S - Sale+OE $30.00 -814 0 -100% -$24.4K
D 2024-10-22 2024-10-18 ELVN Hohl Benjamin CFO M - OptEx $0.00 -814 180.1K -0.5% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-10-18 M A 814 $2.48 814 D — —
2 Common Common Stock 2024-10-18 S D 814 $30.00 0 D — — (F2) This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3 Derivative Stock Option (right to buy) 2024-10-18 M D 814 $0.00 180,056 D $2.48 · — to 2031-08-02 814 Common Stock (F3) The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.